Alnylam Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $260
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $307
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $400
B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $282 to $295
Alnylam Pharma (ALNY) Gets a Buy From TD Cowen
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $295
Alnylam Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
Alnylam Pharmaceuticals Price Target Raised to $280.00/Share From $248.00 by JP Morgan
JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $280
Alnylam Pharmaceuticals Analyst Ratings
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating
Alnylam Pharmaceuticals Analyst Ratings